Follicular Lymphoma

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking combination therapy.

The FDA issued a complete response letter to the odronextamab application in follicular lymphoma, rejecting the drug for a second time in this patient population.

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed follicular lymphoma.

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular lymphoma compared to watchful waiting. Maintenance rituximab showed no added benefit over induction alone.

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after phase 3 trial enrollment milestone.

Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

This FDA approval marks the first subcutaneous bispecific antibody to be approved in patients with relapsed/refractory follicular lymphoma.

Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma.

Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.

The combination of zanubrutinib and obinutuzumab is now an approved treatment option for adult patients with relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.

If FDA-approved, epcoritamab would be the first and only subcutaneous bispecific antibody indicated for the treatment of adult patients with relapsed/refractory follicular lymphoma after 2 rounds of previous therapy.

In an interview with Targeted Oncology, Stephen J. Schuster, MD, further discussed the rationale and findings from the phase 2 ELARA study of tisa-cel among patients with follicular lymphoma.

In an interview with Targeted Oncology, Franck Morschhauser, MD, PhD, discussed the high complete response rates and durable remissions seen with lisocabtagene maraleucel in patients with high-risk relapsed/refractory follicular lymphoma.

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

Investigators report no new safety signals in patients with relapsed/refractory follicular lymphoma following treatment with tisagenlecleucel infusion.

The FDA breakthrough drug designation for epcoritamab in follicular lymphoma was supported by findings from the phase 1/2 EPCORE NHL-1 study.

Priority review to the biologics license application for odronextamab has been granted by the FDA for adult patients with follicular lymphoma and diffuse large B-cell lymphoma.

John M. Burke, MD, discusses how Bruton tyrosine kinase inhibitors have demonstrated unexpected promise in treating follicular lymphoma, challenging previous assumptions in the field of oncology.

CD19-direct CAR T-cell therapies and the CD20-targeted bispecific antibodies both represent a viable treatment choice for patents with relapsed/refractory follicular lymphoma.

In an interview, Brad S. Kahl, MD, discussed the changes in the field of follicular lymphoma and how physicians should approach treatment.

The use of bispecific antibodies has the potential to revolutionize the management of FL.

Treatment with liso-cel had a manageable safety profile with no new safety signals in patients with relapsed/ refractory follicular lymphoma.

Epcoritamab plus rituximab/lenalidomide demonstrated antitumor activity in patients with relapsed/refractory follicular lymphoma, including those with high-risk features.